StimLabs diabetic foot ulcer trial - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

PMV’s $79.4m cash pile now hinges on rezatapopt’s 2027 ovarian cancer FDA bid

NFI Group’s backlog shrank 10.6% as earnings surged. How can both be true?

Frontera Energy’s post-divestment strategy is shifting toward infrastructure growth, with Puerto Bahía, its ODL pipeline stake and a planned LNG regasification project expected to drive future cash flow after the company returned C$590 million to shareholders. Representative image.

Frontera Energy (TSX: FEC) Q2 puts early-2027 LNG launch in focus

Shell’s Wild Coast offshore exploration plans have suffered a major setback after South Africa’s Constitutional Court blocked the disputed exploration right, sharpening scrutiny of how the country balances energy investment with environmental safeguards and community consultation. Representative image.

Shell plc (LSE: SHEL) blocked from Wild Coast exploration as South Africa faces investment test

StimLabs' CAMPSTIM trial is setting new standards in diabetic foot ulcer treatment with innovative tissue products

Read More

Healthcare Industry News

Revolutionary breakthrough? New trial by StimLabs could change future of diabetic wound care

StimLabs, a pioneer in regenerative medicine, has initiated the CAMPSTIM trial, a groundbreaking multi-center randomized controlled trial aimed…

byPallavi Madhiraju

July 20, 2024

web analytics